Researchers at Mount Sinai have developed a novel approach to cancer immunotherapy, injecting immune stimulants directly into a tumor to teach the immune system to destroy it and other tumor cells throughout the body.
The “in situ vaccination” worked so well in patients with advanced-stage lymphoma that it is also undergoing trials in breast and head and neck cancer patients, according to a study published in Nature Medicine in April.
The treatment consists of administering a series of immune stimulants directly into one tumor site. The first stimulant recruits important immune cells called dendritic cells that act like generals of the immune army. The second stimulant activatesthe dendritic cells, which then instruct T cells, the immune system’s soldiers, to kill cancer cells and spare non-cancer cells. This immune army learns to recognize features of the tumor cells so it can seek them out and destroy them throughout the body, essentially turning the tumor into a cancer vaccine factory.
“The in situ vaccine approach has broad implications for multiple types of cancer,” said lead author Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This method could also increase the success of other immunotherapies such as checkpoint blockade.”
After testing the lymphoma vaccine in the lab, it was tested in 11 patients in a clinical trial. Some patients had full remission from months to years. In lab tests in mice, the vaccine drastically increased the success of checkpoint blockade immunotherapy, the type of immunotherapy responsible for the complete remission of former President Jimmy Carter’s cancer and the focus of the 2018 Nobel Prize in Medicine.
A clinical trial for lymphoma, breast, and head and neck cancer patients opened in March to test the vaccine with checkpoint blockade drugs. Because the combined immune therapy was at least three times more powerful than either checkpoint blockade or the vaccine by themselves, researchers are extremely optimistic about how effective this may be in patients in this new trial. The in situ vaccine is also being tested in the lab in liver and ovarian cancer.
Learn more: Mount Sinai Researchers Develop Treatment That Turns Tumors Into Cancer Vaccine Factories
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- Man’s ‘bump on head’ turns out to be sign of skin canceron April 26, 2024 at 6:01 am
A man has revealed how his “bump on the head” turned out to be a sign of potentially deadly skin cancer. Steve Young, 52, from Stevenage, was shocked to discover the bump on the top of his head, he'd ...
- Headline: UK cancer patient pioneers groundbreaking skin cancer vaccine trialon April 26, 2024 at 5:16 am
A novel immunotherapy trial, using mRNA technology like in COVID vaccines, aims to prevent skin cancer recurrence. The trial combines a personalized mRNA vaccine with Keytruda, blocking an immune ...
- Can vitamin D help fight cancer?on April 25, 2024 at 9:45 pm
When his colleague Evangelos Giampazolias, now at the Cancer Research UK Manchester Institute, discovered that switching off the gene which provides instructions to make the aptly named vitamin ...
- Conference MDAngle: AUA 2024 Metastatic Prostate Canceron April 25, 2024 at 5:00 pm
These include updates on PSMA PET imaging, new data on PARP inhibitors, and updates from trials evaluating combination therapies. Coming soon: Dr Kelvin Moses will reflect on how new data from AUA ...
- These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)on April 25, 2024 at 2:49 pm
Meeting of ASCO is a major event for clinicians and researchers in the field of oncology. Explore more details here.
- FDA Approves New Type of Immunotherapy for Early Bladder Canceron April 25, 2024 at 1:19 pm
Anktiva, an IL-15 agonist, also shows promise for other malignancies, including non-small-cell lung cancer, and even for HIV.
- Vitamin D may balance gut microbiome to give cancer immunotherapy a booston April 25, 2024 at 12:30 pm
A new study in mice found that dietary vitamin D plays a role in balancing the gut microbiome and improving the way cancer immunotherapy works to fight tumors.
- Unlocking Vitamin D’s Hidden Role in Cancer Immunityon April 25, 2024 at 10:59 am
New research links vitamin D with improved cancer immunity in mice through enhancement of specific gut bacteria. Researchers at the Francis Crick Institute, the National Cancer Institute (NCI) of the ...
- Immunotherapy Combination Approved for Non-Muscle Invasive Bladder Canceron April 24, 2024 at 2:43 am
FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients.
- AI could predict whether cancer treatments will work, experts say: ‘Exciting time in medicine'on April 23, 2024 at 3:00 am
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.
via Bing News